Document Detail

Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
MedLine Citation:
PMID:  3881176     Owner:  NLM     Status:  MEDLINE    
A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma, comparing a combination of doxorubicin and lomustine (DC) with cyclophosphamide and 5-FU (CF). Patients were assessed objectively (employing National Prostate Cancer Project criteria) and subjectively (using a numerical scoring scheme). Each regimen was well tolerated with acceptable levels of myelosuppression. The objective partial response rate was 57% for DC and 8% for CF. Objective stabilization occurred, respectively, in 14% and 44% of the patients. Similarly, DC demonstrated a significantly superior subjective response rate (partial plus complete) of 82%, compared to 48% for CF. Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival. Overall, there was no significant difference in survival between the two arms, reflecting the similarity between DC and CF in total objective response rate (partial response plus stable disease). DC provided superior palliation and was well tolerated by an essentially geriatric population.
J P Page; J A Levi; R L Woods; M N Tattersall; R M Fox; A S Coates
Related Documents :
6404866 - Do prostatic biopsies 12 months or more after external irradiation for adenocarcinoma, ...
7280246 - Computed tomography in the evaluation, staging, and therapy of carcinoma of the bladder...
10387966 - Treatment of androgen-independent prostate cancer.
21696826 - Outcome of older adults with cytogenetically normal aml (cn-aml) and flt3 mutations.
15841636 - Implications of popliteal lymph node detected by sentinel lymph node biopsy.
16209076 - Role of lymphoscintigraphy for selective sentinel lymphadenectomy.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Cancer treatment reports     Volume:  69     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1985 Jan 
Date Detail:
Created Date:  1985-03-06     Completed Date:  1985-03-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  105-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Clinical Trials as Topic
Cyclophosphamide / administration & dosage,  adverse effects
Doxorubicin / administration & dosage,  adverse effects
Drug Resistance
Estrogens / therapeutic use
Fluorouracil / administration & dosage,  adverse effects
Leukocyte Count
Lomustine / administration & dosage,  adverse effects
Middle Aged
Nausea / chemically induced
Neoplasm Metastasis
Platelet Count
Prostatic Neoplasms / drug therapy*,  mortality,  pathology
Random Allocation
Vomiting / chemically induced
Reg. No./Substance:
0/Estrogens; 13010-47-4/Lomustine; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 51-21-8/Fluorouracil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carc...
Next Document:  Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carci...